BCL2 and neoplasm: Bcl-2 staining was positive in 13 of 32 (40.6%) primary tumours from patients with no response (NC+PD) to immunotherapy and in 0 (0%) of eight responders (CR+PR) (P=0.0373) (Tables 2, 3).